Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- Trial result Spotlight
Multiple solid tumors
NT-175 (TP53 R175H–HLA-A*02:01 eTCR; TGFβR2-knockout) drives 47.6% ORR across refractory solid tumors (83% PR in PDAC)
NT-175 is an autologous CRISPR/Cas9-edited engineered TCR T-cell therapy targeting the TP53 R175H neoantigen in an HLA-A*02:01-restricted manner, with endogenous TGFβR2 deleted (to reduce TGF-β–mediated suppression)…
NCT05877599 - Trial result Spotlight
Multiple solid tumors
HCB101 (SIRPα–IgG4 Fc; CD47 checkpoint blocker) shows early monotherapy PRs and high combo disease control in gastric cancer
HCB101 is a CD47–SIRPα axis inhibitor (engineered SIRPα–IgG4 Fc fusion) designed to preserve pro-phagocytic macrophage activity while minimizing red-blood-cell binding/hematologic toxicity. In the first-in-human…
NCT05892718 - Trial result Spotlight
Multiple solid tumors
Darlifarnib (KO-2806) FTI (RHEB/mTORC1) + adagrasib drives 67% ORR in KRAS G12C NSCLC (Ph1 FIT-001)
Darlifarnib (KO-2806) is a next-generation farnesyl transferase inhibitor designed to block farnesylation-dependent RHEB signaling and dampen mTORC1 activity (a proposed resistance node to KRAS G12C inhibition); in…
NCT06026410 - Trial result Spotlight
Multiple solid tumors
SIM0505 (anti-CDH6 topo-I ADC) drives 37% PRs in heavily pretreated gynecologic tumors
SIM0505 is a first-in-class cadherin-6 (CDH6)–targeted antibody–drug conjugate delivering the novel topoisomerase I payload CPT116; it was evaluated in a global Phase I first-in-human dose-escalation study in…
NCT06792552 - Trial result Spotlight
Multiple solid tumors
TILScore-Guided TIL Therapy Produces 33% ORR in Checkpoint-Refractory Solid Tumors
TILScore is an in situ transcriptomic biomarker used to select a metastasis for autologous TIL harvest and “reactive-enriched” manufacturing before lymphodepletion, TIL infusion, and high-dose IL-2. In a…
NCT03935893 - Trial result
Multiple solid tumors
Larotrectinib (TRK inhibitor) delivers 65% ORR and 42-mo DoR in non-primary CNS NTRK fusion cancers
Larotrectinib (laro) is a first-in-class, highly selective TRKA/B/C (NTRK1/2/3) inhibitor evaluated in an updated pooled analysis of 3 trials (SCOUT/NAVIGATE/LOXO-TRK-14001; data cutoff July 20, 2025) in adult and…
- Trial result
Multiple solid tumors
Mecbotamab vedotin (CAB-AXL-ADC) delivers 17.6-mo median OS in heavily pretreated bone sarcomas
Mecbotamab vedotin (Mec‑V; BA3011) is a low-pH conditionally binding AXL-targeted antibody–drug conjugate (ADC) designed to preferentially engage AXL in the acidic tumor microenvironment and limit off-tumor toxicity.…
NCT03425279 - Trial result
Multiple solid tumors
Belzutifan (HIF-2α inhibitor) Delivers 6-Year, Surgery-Sparing Control in VHL RCC/CNS HB/pNET
Belzutifan is an oral, potent hypoxia-inducible factor 2α (HIF-2α) inhibitor evaluated in the open-label, single-arm Phase 2 LITESPARK-004 study (NCT03401788) for germline VHL patients with nonmetastatic RCC not…
NCT03401788 - Trial result
Multiple solid tumors
Stop vs continue PD-1/PD-L1 at 1 year shows similar “cure” and PFS, with OS signal favoring stopping
In the randomized Phase 3 NCT04157985 trial, patients with advanced solid tumors who had ≥SD after 1 year of standard-of-care PD-1/PD-L1 inhibitor therapy were randomized to stop vs continue immunotherapy (n=161;…
NCT04157985 - Trial result
Multiple solid tumors
Abemaciclib (CDK4/6 inhibitor) + hormonal therapy posts 17.5-mo mPFS in recurrent LGSOC, biomarker-enriched benefit in NSMP ER+ endometrial cancer
Abemaciclib is an oral CDK4/6 inhibitor given at 150mg BID with hormonal therapy in a single-center Phase II study enrolling ER+ recurrent endometrial cancer (EC), low-grade serous ovarian cancer (LGSOC), and…
NCT04469764 - Trial result
Multiple solid tumors
ATM-mutant tumors: 4Gy×2 palliative RT delivers 83% 6‑mo local control with near-zero toxicity
This is a single-arm Phase II basket trial testing genomically guided RT dose de-escalation in metastatic solid tumors with pathogenic ATM mutations (NCT05010031): all patients received 4Gy×2 (8Gy total) to a…
NCT05010031 - Trial result
Multiple solid tumors
Zidesamtinib (NVL-520), a ROS1-selective/TRK-sparing TKI, delivers 40% ORR across non-NSCLC ROS1+ solid tumors
Zidesamtinib is an oral next-generation ROS1 tyrosine kinase inhibitor designed to be highly ROS1-selective and TRK-sparing (to avoid TRK-mediated neurotoxicity), evaluated in the global Phase 1/2 ARROS-1 basket…
NCT05118789 - Trial result
Multiple solid tumors
NP-G2-044 (fascin inhibitor) + anti–PD-1 drives 50% CR-heavy responses in PD-1–resistant CSCC
NP-G2-044 is an oral, first-in-class fascin inhibitor designed to activate intratumoral dendritic cells (DCs) and enhance IL-12/IFN-γ–dependent antitumor immunity, potentially re-sensitizing tumors to PD-1 blockade;…
NCT05023486 - Trial result
Multiple solid tumors
NTX1088 (anti-PVR/CD155) + pembrolizumab drives 17% confirmed PRs in PD-(L)1–refractory solid tumors
NTX1088 is a first-in-class monoclonal antibody targeting PVR (CD155), intended to restore DNAM1 (CD226)-mediated T/NK-cell activity and counter multiple PVR-driven inhibitory axes (e.g., TIGIT/CD96). In the Phase…
NCT05378425 - Trial result
Multiple solid tumors
Efdelikofusp alfa (CD80–IL-2v2 immunocytokine) + pembrolizumab shows 40% ORR in heavily pretreated ccRCC
Efdelikofusp alfa (GI-101A) is a CD80-IgG4 Fc–fused engineered IL-2 variant (reduced IL-2Rα affinity) designed to both antagonize CTLA-4–mediated suppression and preferentially expand CD8+ T/NK cells over Tregs; it…
NCT04977453 - Trial result
Multiple solid tumors
BAL0891 (dual TTK/PLK1 spindle-checkpoint inhibitor) sets 160 mg RP2D with early disease control in refractory solid tumors
BAL0891 is a first-in-class dual threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) inhibitor designed to disrupt the spindle assembly checkpoint (SAC) and drive mitotic catastrophe; in the ongoing,…
NCT05768932 - Trial result
Multiple solid tumors
IMA401 MAGEA4/8 TCER posts 33% ORR in HNSCC with mostly low‑grade CRS and no ICANS
IMA401 is a first-in-class, HLA-A*02:01-restricted MAGEA4/8 TCR–based bispecific T-cell engager (TCER) with an Fc for half-life extension and a low-affinity CD3 T-cell–recruiting domain intended to improve…
NCT05359445 - Trial result
Multiple solid tumors
PeptiCRAd-1 (CD40L/OX40L oncolytic Ad) + NY-ESO-1/MAGE-A3 peptides drives early immune priming with 40% responses on pembrolizumab
PeptiCRAd-1 is a conditionally replicating oncolytic adenovirus engineered to express CD40L and OX40L and “decorated” with NY-ESO-1 and MAGE-A3 peptides to boost tumor antigen–specific T-cell priming; in VALO-001…
NCT05492682 - Trial result
Multiple solid tumors
EIK1003 (PARP1-selective inhibitor) + weekly paclitaxel shows 23% ORR with manageable myelosuppression in platinum-resistant OC/HER2(–) BC
EIK1003 is a potent PARP1-selective inhibitor designed to reduce PARP2-linked myelosuppression seen with “classical” PARP1/2 inhibitors and potentially enable combination with cytotoxic chemotherapy. In the…
NCT06253130 - Trial result
Multiple solid tumors
UCMYM802 armored MSLN CAR-T (mRNA-electroporated; LACO-Stim) shows 28.6% ORR in refractory solid tumors—CRS (incl grade 4) is the main limiter
UCMYM802 is an autologous mesothelin (MSLN)-targeted CAR-T made via mRNA electroporation and “armored” with a lymphocyte–antigen-presenting cell costimulatory (LACO-Stim) module; it was evaluated in a first-in-human…
NCT06256055 - Trial result
Multiple solid tumors
CTX-8371 PD-1×PD-L1 bispecific (CD80-CD28–enabling) shows 20% ORR post–checkpoint failure in Phase 1
CTX-8371 is a first-in-human PD-1×PD-L1 bispecific antibody designed to deliver dual checkpoint blockade while enabling CD80–CD28 engagement and promoting PD-1 cleavage from activated T cells. In a 3+3 Phase 1…
NCT06150664 - Trial result
Multiple solid tumors
BG-C9074 B7-H4–targeting topo I ADC shows 28.1% confirmed ORR (34.5% in ovarian; 31.3% in TNBC) in heavily pretreated solid tumors
BG-C9074 is a B7-H4–directed antibody-drug conjugate delivering a topoisomerase I inhibitor payload; in the ongoing first-in-human Phase 1 BG-C9074-101 dose-escalation/safety-expansion study (NCT06233942), patients…
NCT06233942 - Trial result
Multiple solid tumors
OP-3136 (oral KAT6A/B inhibitor) shows early tumor shrinkage with low DLT signal in heavily pretreated ER+/HER2− ABC and mCRPC
OP-3136 is a potent, selective, oral small-molecule inhibitor of the histone acetyltransferases KAT6A/B, evaluated in a Phase 1 first-in-human Bayesian dose-escalation study as monotherapy in advanced solid tumors…
NCT06784193 - Trial result
Multiple solid tumors
DM002 (anti‑MUC1/HER3 BsADC; Topo‑I payload) Shows 20% PRs and 73% DCR in Early Solid-Tumor Readout
DM002 is a bispecific antibody–drug conjugate targeting MUC1 and HER3 (average DAR≈8) and delivering a DNA topoisomerase I inhibitor payload (BCPT02) via the BLD1102 linker/payload system; it was evaluated in a…
NCT06751329 - Trial result
Multiple solid tumors
DM005 (EGFR/c-MET bispecific topo-I ADC) shows 46% unconfirmed ORR in heavily pretreated EGFRm NSCLC (FIH)
DM005 is a first-in-human anti-EGFR/c-MET bispecific antibody–drug conjugate (DAR≈4) delivering a DNA topoisomerase I inhibitor payload (BCPT02) via the BLD1102 linker/payload system, designed to exploit EGFR/c-MET…
NCT06515990 - Trial result
Multiple solid tumors
Eftilagimod alfa (soluble LAG-3/MHC class II APC activator) links early ALC rise to ~7.7-mo OS gain across metastatic cancers
Eftilagimod alfa (E; soluble LAG-3 fusion protein that agonizes a subset of MHC class II on antigen-presenting cells to drive Th1/T-cell activation) was analyzed across 5 studies in late-stage metastatic…
- Trial result
Multiple solid tumors
ODM-212 (pan-TEAD/YAP–TAZ pathway inhibitor) posts 27.8% ORR in evaluable mesothelioma in first-in-human TEADES
ODM-212 is an oral small-molecule pan-TEAD (TEAD1–4) inhibitor designed to shut down YAP1/TAZ-driven Hippo-pathway transcription and was evaluated in the multi-site, open-label TEADES first-in-human Phase 1/2 (BOIN…
NCT06725758 - Trial result
Multiple solid tumors
T-DXd Delivers 58% ORR and 15.7-Month PFS in China HER2 IHC3+ Pan-Tumor Cohort
Trastuzumab deruxtecan is a HER2-directed ADC with a topoisomerase I payload, tested in DESTINY-PanTumor03 Part 1 (NCT06271837) in China among HER2 IHC3+ unresectable/metastatic solid tumors excluding breast and…
NCT06271837 - New trial Spotlight
Multiple solid tumors
Phase 1 CLSP-5282 KRAS G12V–HLA-A03:01 T-cell engager in solid tumors
This Phase 1 open-label, multicenter, dose-escalation and expansion trial (SENTINEL-101) evaluates CLSP-5282 in adults whose advanced/metastatic solid tumors harbor KRAS G12V and who are HLA-A03:01 positive.…
NCT07650357 First-in-human - New trial
Multiple solid tumors
Phase 1 Lattice Radiotherapy (spatially fractionated IMRT) adds vertex “boosts” for bulky tumors
This Duke University pilot interventional study tests whether adding Lattice Radiation Therapy (LRT)—a spatially fractionated form of intensity-modulated radiation therapy (IMRT)—to standard palliative external-beam…
NCT07647679 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.